Attention-Deficit/Hyperactivity Disorder (ADHD)
23
3
3
12
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
4.3%
1 terminated out of 23 trials
92.3%
+5.8% vs benchmark
26%
6 trials in Phase 3/4
50%
6 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 12 completed trials
Clinical Trials (23)
Occupational Therapy-Based Dance Program for Children With ADHD
Home Play-based Intervention for Parents and Infants
Cannabigerol Oil for Adolescents With ADHD (CAN-ADHD)
Finding Alternatives to Standard Treatment for Attention-Deficit Hyperactivity Disorder
The ADHD Kids´ Study for Children 9-12 Years of Age
Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD
Clinical Trial to Investigate the Safety and Efficacy of Two Dexamfetamine Sulfate Formulations in Adults With ADHD and Moderate to Severe Depression
Treating Young Children With Attention Deficit Hyperactivity Disorder
Reward Effects on Cognition, Motor Skills, and Motivation in Children
Evaluation of Immediate-Release Viloxazine in Adults With ADHD
Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD
Virtual Reality for Parent Training Intervention
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD
Efficacy of an Organizational Skills Intervention for Middle School Students With ADHD
A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED)
Does Active Parent Involvement in Deliberation and Choice Improve Medication Persistence for Their Child With ADHD
Evaluating Clinical Outcomes of Treatment Effectiveness for Children and Adults With ADHD
Treatment of College Students With Attention-Deficit/Hyperactivity Disorder (ADHD) Using OROS Methylphenidate
Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.